Objective response to hydroxyurea in a patient with heavily pre-treated aggressive fibromatosis
The disease control rates of the medical treatments, such as low-dose chemotherapy with methotrexate plus vinblastine or vinorelbine, imatinib, sorafenib, pazopanib, nilotinib
Nirogacestat for Adults with Desmoid Tumor/Aggressive Fibromatosis (DeFi), an international, phase 3, randomized, placebo-controlled study
Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable
Overview: Desmoid-type (aggressive) fibromatosis (desmoid tumor) is a soft tissue neoplasm that can occur in both children and adults
Although aggressive fibromatosis (AF) is histological classified as a low grade soft tissue sarcoma it can clinically lead to severe morbidity, functional impairment and even death when located at anatomical critical sites
We report the case of a 26-year-old Tunisian female who presented Europe PMC is an archive of life sciences journal literature
DF is a rare tumor, with reported incidence of 2–4 per million population and account for 0
Objective response to hydroxyurea in a patient with heavily pre-treated aggressive fibromatosis
Do,BarisTurkbey,Paul S
Because of its low incidence and variable behavior, DTF is often first seen by physicians who are not familiar with it, and recent advances in understanding this disease have led to changes in treatment approaches
Surgery is the mainstay of treatment but complete tumor resection is often not easy to achieve Desmoid-type fibromatosis (DF) is a rare type of soft tissue tumour
A desmoid tumor can occur anywhere in the body since connective tissue is found everywhere in your body
Other pharmacologic agents have been considered in the treatment of desmoid tumors in children, including hydroxyurea and interferon alpha